$5.4 B

FGEN Mkt cap, 18-Jul-2018

$31.9 M

FibroGen Revenue Q1, 2018
FibroGen Net income (Q1, 2018)-41.4 M
FibroGen EBIT (Q1, 2018)-40.6 M
FibroGen Cash, 31-Mar-2018659 M

FibroGen Revenue Breakdown

Embed Graph

FibroGen revenue breakdown by geographic segment: 85.6% from Europe, 14.4% from Japan and 0.1% from Other

FibroGen Income Statement

Annual

USDFY, 2015FY, 2016FY, 2017

Revenue

180.8 m179.6 m125.7 m

Revenue growth, %

(1%)

R&D expense

214.1 m187.2 m196.5 m

General and administrative expense

44.4 m46 m51.8 m

Operating expense total

258.5 m233.2 m248.3 m

EBIT

(77.6 m)(53.7 m)(122.6 m)

EBIT margin, %

(43%)(30%)(98%)

Interest expense

11 m10.7 m9.7 m

Pre tax profit

(85.5 m)(61.8 m)(125.9 m)

Income tax expense

242 k(71 k)321 k

Net Income

(85.8 m)(61.7 m)(126.2 m)

Quarterly

USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Revenue

16.3 m120.6 m19.5 m28.3 m89.3 m30.1 m26.9 m29 m31.9 m

R&D expense

50.5 m51.6 m52.1 m43.7 m52.4 m40.6 m46.7 m47 m57 m

General and administrative expense

10.5 m9.7 m11.2 m11.4 m10.4 m11.6 m11.5 m13.4 m15.6 m

Operating expense total

61 m61.2 m63.3 m55.1 m62.8 m52.2 m58.3 m60.4 m72.5 m

EBIT

(44.7 m)59.3 m(43.8 m)(26.8 m)26.5 m(22.1 m)(31.4 m)(31.4 m)(40.6 m)

EBIT margin, %

(274%)49%(224%)(95%)30%(73%)(117%)(108%)(127%)

Interest expense

2.8 m2.8 m2.8 m2.8 m2.4 m2.8 m2.4 m2.8 m2.8 m

Interest income

843 k707 k1.5 m

Pre tax profit

(46.6 m)57.3 m(45.1 m)(28.1 m)24.2 m(24 m)(33.1 m)(33.1 m)(41.3 m)

Income tax expense

(113 k)158 k60 k48 k99 k

Net Income

(46.4 m)57.1 m(45.1 m)(27.8 m)24.3 m(24.2 m)(33.2 m)(33.2 m)(41.4 m)

FibroGen Balance Sheet

Annual

USDFY, 2015FY, 2016FY, 2017

Cash

153.3 m173.8 m673.7 m

Accounts Receivable

15.4 m10.4 m8.5 m

Inventories

4 m2.9 m

Current Assets

200.6 m266.5 m749 m

PP&E

129 m123.7 m129.5 m

Total Assets

470.6 m469.6 m898.7 m

Accounts Payable

6.5 m6.2 m5.5 m

Current Liabilities

67.2 m65.1 m77.3 m

Total Liabilities

294.4 m316.2 m

Additional Paid-in Capital

586.6 m625.9 m1.2 b

Retained Earnings

(408.1 m)(469.7 m)(595.9 m)

Total Equity

177.6 m155.8 m563.2 m

Financial Leverage

2.7 x3 x1.6 x

Quarterly

USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

128.4 m236.5 m208.7 m141 m190.4 m198.3 m170.6 m290.3 m659 m

Accounts Receivable

7 m12.2 m7.4 m5.9 m18.1 m7.7 m7.2 m8.9 m10 m

Current Assets

155.4 m263.6 m232.6 m184 m252.3 m253.5 m256.6 m371.3 m717.2 m

PP&E

131.7 m130.5 m129.6 m127.6 m126.3 m124.8 m122.8 m122.6 m129.9 m

Total Assets

435.5 m541.4 m499.2 m442.5 m499.1 m486.2 m441.8 m542.6 m867.6 m

Accounts Payable

2.4 m3.9 m4.2 m1.5 m3.5 m2 m3 m3.3 m3.5 m

Current Liabilities

54 m63.5 m59 m58.3 m66.4 m61.7 m60.1 m59.8 m83.3 m

Total Liabilities

231.7 m268.5 m262.7 m266.3 m286.8 m288.6 m290.8 m293.3 m348.8 m

Additional Paid-in Capital

553.4 m565.2 m575 m593.9 m605.1 m614.8 m635 m766.9 m1.2 b

Retained Earnings

(368.7 m)(311.6 m)(356.7 m)(435.9 m)(411.6 m)(435.7 m)(502.9 m)(536.1 m)(670.8 m)

Total Equity

203.9 m272.9 m217.3 m157 m193.1 m178.3 m131.7 m230.1 m499.5 m

Financial Leverage

2.1 x2 x2.3 x2.8 x2.6 x2.7 x3.4 x2.4 x1.7 x

FibroGen Cash Flow

Annual

USDFY, 2015FY, 2016FY, 2017

Net Income

(85.8 m)(61.7 m)(126.2 m)

Depreciation and Amortization

5.7 m6 m6.1 m

Accounts Receivable

(2 m)5 m2 m

Inventories

978 k1.1 m

Accounts Payable

2 m(298 k)(714 k)

Cash From Operating Activities

(18.6 m)7.1 m(66.5 m)

Purchases of PP&E

(2 m)(1.3 m)(8.5 m)

Cash From Investing Activities

(5.9 m)6.6 m69.9 m

Cash From Financing Activities

12.3 m6.7 m496.5 m

Quarterly

USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Net Income

(46.4 m)10.7 m(34.4 m)(27.8 m)(3.5 m)(27.7 m)(33.2 m)(66.3 m)(41.4 m)

Depreciation and Amortization

2.8 m4.2 m1.5 m3 m4.5 m1.5 m3.1 m1.5 m

Accounts Receivable

7 m1.3 m6.1 m9.5 m(2.7 m)7.7 m3.2 m1.5 m(1.5 m)

Accounts Payable

2.4 m(636 k)(317 k)(5 m)(3 m)(4.5 m)(3.3 m)(3 m)(2 m)

Cash From Operating Activities

58.9 m20.7 m(17.3 m)27.4 m25.7 m(27.1 m)(46.9 m)(32 m)

Purchases of PP&E

(989 k)(1.7 m)(898 k)(1 m)(1.1 m)(636 k)(1.6 m)(1.8 m)

Cash From Investing Activities

6 m14.3 m5.1 m7.2 m15.7 m23.4 m40.3 m15.3 m

Cash From Financing Activities

5.4 m8.2 m(149 k)2.5 m3.6 m574 k123 m2 m

FibroGen Ratios

USDY, 2018

Financial Leverage

1.7 x
Report incorrect company information

FibroGen Operating Metrics

FY, 2016

Facilities

2

Patent Portfolios

4

Phase II Trials Products

1

Phase III Trials Products

1
Report incorrect company information